We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Cetylated Fatty Acids (CMO)
A cetylated fatty-acid ester (often sold as 'Celadrin') marketed for arthritis and joint pain. A few small RCTs — oral and topical — report improved knee range-of-motion and function, but independent systematic reviews rate the overall evidence as 'limited' or unproven.
What the evidence says
Most Cetyl Myristoleate studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2002–2006 with a typical study size of 40 participants.
Based on 5 studies · 2 RCTs · 132 total participants
Confidence
LowBy outcome
Cetyl Myristoleate has an evidence score of 3/10 — emerging evidence based on 5 indexed studies. A cetylated fatty-acid ester (often sold as 'Celadrin') marketed for arthritis and joint pain. A few small RCTs — oral and topical — report improved knee range-of-motion and function, but independent systematic reviews rate the overall evidence as 'limited' or unproven. Representative study: PMID 16859534.
The commonly studied dose of Cetyl Myristoleate is Oral: ~350-550 mg cetylated fatty acids daily (trial-typical); Topical: cream applied twice daily. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Explore: Best supplements for Body Health
Last reviewed June 2026 · evidence from 5 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Cetyl myristoleate (CMO) is a fatty-acid ester first described in mice, now sold orally and as a topical cream (commonly branded Celadrin) for osteoarthritis and joint discomfort. The proposed rationale is anti-inflammatory lubrication of joint tissue, though the mechanism in humans is not well established. The evidence base is a small cluster of trials — most notably an oral RCT (Hesslink 2002) showing improved knee flexion and function, and topical-cream studies from the Kraemer group at UConn showing reduced pain and better postural stability. These are encouraging but small, several share authors/industry ties, and independent appraisals are cautious: a 2006 systematic review of OA nutraceuticals (Ameye) rated the evidence for cetyl myristoleate as only 'limited,' and a clinical review (Morelli 2003) flatly stated it had 'no proven clinical usefulness.' Net: a plausible, modestly-studied joint supplement that is far from established.
Cetylated fatty acids are thought to modulate joint inflammation and improve tissue lubrication, though the human mechanism is not well characterized.
Hypothesized to improve the gliding properties of joint surfaces, contributing to better range of motion.
How Cetyl Myristoleate works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Oral: ~350-550 mg cetylated fatty acids daily (trial-typical); Topical: cream applied twice daily
Take with food
| Form | Type |
|---|---|
| 🧴Oral cetylated fatty acid complex (or topical cream) | Recommended |
| 🧴Topical cream | Alternative |
Both forms studied in small trials; evidence rated limited.
Minimum: 4 weeks
Optimal: 10 weeks
Cycling: Not required
Note: Oral with food; topical applied twice daily to the joint.
Dose-response data unavailable. The current published research for Cetyl Myristoleate does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
An oral RCT reported significantly greater knee flexion versus placebo.
Topical-cream studies reported reduced pain and improved stair-climbing, balance, and postural stability.
Not studied — avoid.
Often used as an NSAID alternative; no significant interaction reported, but combining is unstudied.
Tip: Take with food
Tip: Discontinue if irritation occurs
Both are widely used oral joint supplements targeting osteoarthritis symptoms by different proposed mechanisms.
Layered symptomatic joint support.
MSM is another popular OA supplement often stacked with fatty-acid joint products.
Complementary joint-comfort support (modest evidence for each).
The best time to take Cetyl Myristoleate is with meals. Take it with food. As a fatty-acid ester, oral CMO is taken with food; topical cream is applied directly to the affected joint twice daily.
Cetyl Myristoleate is generally well-tolerated and considered safe for most healthy adults at recommended doses. The most commonly reported side effects are mild GI upset (oral), local skin irritation (topical). Use caution if any of these apply to you: Pregnancy/breastfeeding (not studied).
Hydrolyzed peptides that rebuild skin elasticity, reduce joint pain, and strengthen bone density — results build over 8-12 weeks.